Adipose-derived stromal cells: Their identity and uses in clinical trials, an update

Table 4 Clincial trials using adipose-derived stromal cell

Clinical trials with ADSC	Design	Results	Ref
Maxillary reconstruction	Autologous ADSC case report	Success	{Mesimaki, 2009 #480}
Cryptoglandular origin fistula with or without Crohn’s disease	Autologous ADSC phase I/II intra-tissue	ADSCs more effective (P = 0.001). Recurrence rate with ADSC = 17.6%	{Garcia-Olmo, 2008 #451; Garcia-Olmo, 2009 #449}
	Autologous ADSC	Ongoing, not recruiting	NCT00115466*
	Phase II, 2 arms (fibrin glue, fibrin glue + ADSC)
Crohn’s disease fistula	Autologous ADSC, phase I and II	Phase I, complete	NCT00992485*
		Phase II recruiting	NCT01011244*
	Autologous ADSC, phase I	Phase I/II recruiting	NCT01157650*
	Allogenic ADSC: phase I/II	recruiting	NCT00999115*
	20 × 106 then 40 × 106
Complex Perianal Fistulas not associated to Crohn’s disease	Autologous ADSC, phase III three arms (fibrine, ADSC, fibrin glue + ADSC; 20 × 106 then 40 × 106 when no effect)	Completed (214 enrolled patients)	NCT00475410*
	Long term safety	Recruiting	NCT01020825*
Depressed Scar	Autologous ADSC predifferentiated towards adipocyte, phase II, III	Complete	NCT00992147*
Chronic critical limb Ischemia	Autologous ADSC, phase I	Recruiting	NCT01211028*
	im 100 × 106
Chronic critical limb Ischemia in diabetic patients	Autologous ADSC, phase I/II	Recruiting	NCT01079403*
	iv administration
Fecal incontinence	Autologous ADSC, phase I	Recruiting	NCT01011686*
GVHD	Autologous ADSC	4/5 alive (after a median follow-up of 40 mo)	{Fang, 2007 #469}
	iv 106/kg
	Autologous ADSC	Recruiting	NCT01222039
	Three arms no administration, iv 106/kg or 3 × 106/kg
Secondary Progressive Multiple Sclerosis	Autologous ADSC phase I/II	Recruiting	NCT01056471*
	3 arms (iv 106 and 4 × 106/kg against no intervention)

The clinical trials that are indexed in this table were retrieved using adipose, derived and stem in clinicaltrial and Pubmed websites. As discussed in the text, there is some confusion about the use of the term adipose-derived stroma/stem cells that can be used for crude SVF. This term should be restricted to cultured adipose derived mesenchymal stem cells and the table lists the trials using such cells (*identifier on Clinicaltrials website: *http://clinicaltrials.gov/ct2/results?term=adipose+derived+cells). ADSC: Adipose-derived stromal cell; GVHD: Graft-versus-host disease.